Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development

The in vivo metabolic clearance in human has been successfully predicted by using in vitro data of metabolic stability in cryopreserved preparations of human hepatocytes. In the predictions by human hepatocytes, the systematic underpredictions of in vivo clearance have been commonly observed among different datasets. The regression-based scaling factor for the in vitro-to-in vivo extrapolation has mitigated discrepancy between in vitro prediction and in vivo observation. In addition to the elimination by metabolic degradation, the important roles of transporter-mediated hepatic uptake and canalicular excretion have been increasingly recognized as a rate-determining step in the hepatic clearance. It has been, therefore, proposed that the in vitro assessment should allow the evaluation of clearances for both transporter(s)-mediated uptake/excretion and metabolic degradation. This review first outlines the limited ability of subcellular fractions such as liver microsomes to predict hepatic clearance in vivo. It highlights the advantages of cryopreserved human hepatocytes as one of the versatile in vitro systems for the prediction of in vivo metabolic clearance in human at the early development stage. The following section discusses the mechanisms underlying the systematic underprediction of in vivo intrinsic clearance by hepatocytes. It leads to the proposal for the assessment of hepatic uptake clearance as one of the kinetically important determinants for accurate predictions of hepatic clearance in human. The judicious combination of advanced technologies and understandings for the drug disposition allows us to rationally optimize new chemical entities to the drug candidate with higher probability of success during the clinical development.

[1]  Wei Zhang,et al.  Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients , 2007, Acta Pharmacologica Sinica.

[2]  H. Greim,et al.  Uptake of taurocholic acid into isolated rat-liver cells. , 1975, European journal of biochemistry.

[3]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[4]  W. Trager,et al.  Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.

[5]  H. Kusuhara,et al.  Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.

[6]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[7]  P. Taylor,et al.  Current progress on esterases: from molecular structure to function. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[8]  H. Strobel,et al.  Extrahepatic drug metabolizing enzymes , 1999, Journal of biochemical and molecular toxicology.

[9]  J. Houston,et al.  PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES , 2005, Drug Metabolism and Disposition.

[10]  D. Oh,et al.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.

[11]  R. Riley,et al.  The pivotal role of hepatocytes in drug discovery. , 2007, Chemico-biological interactions.

[12]  Nicola J Hewitt,et al.  Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum‐free incubations , 2006, The Journal of pharmacy and pharmacology.

[13]  D. Jaeck,et al.  Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  D. Keppler,et al.  Vectorial Transport of the Peptide CCK-8 by Double-Transfected MDCKII Cells Stably Expressing the Organic Anion Transporter OATP1B3 (OATP8) and the Export Pump ABCC2 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  J Brian Houston,et al.  Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.

[16]  T. Kennedy Managing the drug discovery/development interface , 1997 .

[17]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[18]  J. Houston,et al.  Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[20]  B. Telfer,et al.  Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[22]  J. Houston,et al.  Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[23]  G. Tucker,et al.  Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[24]  Y. Sugiyama,et al.  Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.

[25]  R. Obach,et al.  Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[26]  M. Rowland,et al.  Correlation between in‐vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model , 1986, The Journal of pharmacy and pharmacology.

[27]  J B Houston,et al.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  Kiyomi Ito,et al.  Prediction of Human Drug Clearance from in Vitro and Preclinical Data Using Physiologically Based and Empirical Approaches , 2004, Pharmaceutical Research.

[29]  M Rowland,et al.  Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.

[30]  P. Olinga,et al.  Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. , 1998, The Journal of pharmacology and experimental therapeutics.

[31]  Michael S. Roberts,et al.  A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations , 1986, Journal of Pharmacokinetics and Biopharmaceutics.

[32]  I. Phillips,et al.  Differential developmental and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FM04. , 1996, European journal of biochemistry.

[33]  Teruko Imai,et al.  Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine , 2006, Drug Metabolism and Disposition.

[34]  J B Houston,et al.  Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[35]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[36]  A. Galetin,et al.  Prediction of metabolic clearance using fresh human hepatocytes: Comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[37]  Wei Zhang,et al.  SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. , 2007, British journal of clinical pharmacology.

[38]  R. Obach The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[39]  U. Christians,et al.  Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[40]  P. Neuvonen,et al.  Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.

[41]  Y. Sugiyama,et al.  Drug transporters: their role and importance in the selection and development of new drugs. , 2002, Drug metabolism and pharmacokinetics.

[42]  Aleksandra Galetin,et al.  UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES , 2004, Drug Metabolism and Disposition.

[43]  G. L. Kedderis,et al.  Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. , 1999, Chemico-biological interactions.

[44]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[45]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[46]  K. Pang,et al.  THE ROLES OF TRANSPORTERS AND ENZYMES IN HEPATIC DRUG PROCESSING , 2005, Drug Metabolism and Disposition.

[47]  Teruko Imai,et al.  Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.

[48]  J. Tuszynski,et al.  Reassessing Models of Hepatic Extraction , 2003, Journal of biological physics.

[49]  Robert J Riley,et al.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. , 2003, British journal of clinical pharmacology.

[50]  H. Kusuhara,et al.  The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. , 2003, Drug metabolism and pharmacokinetics.

[51]  Chuang Lu,et al.  Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes , 2006, Drug Metabolism and Disposition.

[52]  Albert P. Li,et al.  Human hepatocytes: isolation, cryopreservation and applications in drug development. , 2007, Chemico-biological interactions.

[53]  Kazuya Maeda,et al.  CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[54]  D. Eaton,et al.  Uptake of morphine and nalorphine by isolated rat hepatocytes. , 1978, The Journal of pharmacology and experimental therapeutics.

[55]  T Ishizaki,et al.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.

[56]  K. Nagata,et al.  Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: Comparison among well-stirred, parallel-tube, distributed and dispersion models , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[57]  Andrew Rowland,et al.  Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[58]  R. Weisiger Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Li,et al.  Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. , 1999, Chemico-biological interactions.

[60]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[61]  Ken Grime,et al.  Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.

[62]  D. Keppler,et al.  Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.

[63]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[64]  Y. Sawada,et al.  Dose-dependent hepatic handling of l-propranolol determined by multiple indicator dilution method: influence of tissue binding of l-propranolol on its hepatic elimination. , 1993, Biological and Pharmaceutical Bulletin.

[65]  A. El-Kadi,et al.  Effects of renal diseases on the regulation and expression of renal and hepatic drug-metabolizing enzymes: a review , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  Masato Chiba,et al.  Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[67]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[68]  U. Klotz,et al.  Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.

[69]  J. Houston,et al.  Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[70]  Yuichi Sugiyama,et al.  Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[71]  Kazuya Maeda,et al.  In Vitro–In Vivo Scale‐up of Drug Transport Activities , 2006 .

[72]  F. Oesch,et al.  Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[73]  A. Rettie,et al.  Immunoquantitation of FMO1 in human liver, kidney, and intestine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[74]  J B Houston,et al.  Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.

[75]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[76]  Manfred Kansy,et al.  Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model , 2008, Drug Metabolism and Disposition.

[77]  U. Hofmann,et al.  Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.

[78]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide , 2008, Journal of clinical pharmacology.

[79]  Hyunyoung Jeong,et al.  Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.

[80]  T. Langmann,et al.  Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. , 1997, Biochemical and biophysical research communications.

[81]  J. Miners,et al.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.

[82]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[83]  Y. Sugiyama,et al.  Prediction of in vivo nonlinear first-pass hepatic metabolism of YM796 from in vitro metabolic data. , 1998, The Journal of pharmacology and experimental therapeutics.

[84]  Y. Sugiyama,et al.  Prediction of in vivo biliary clearance from the in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. , 2004, Molecular pharmacology.

[85]  J. Houston,et al.  Prediction of in vivo disposition from in vitro systems: clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. , 1995, The Journal of pharmacology and experimental therapeutics.

[86]  K. Maeda,et al.  Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.

[87]  J. Houston,et al.  In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[88]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[89]  J. Houston,et al.  In vivo clearance of ethoxycoumarin and its prediction from In vitro systems. Use Of drug depletion and metabolite formation methods in hepatic microsomes and isolated hepatocytes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[90]  M. Niemi,et al.  Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.

[91]  P. Neuvonen,et al.  Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.

[92]  Junjeong Choi,et al.  Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans , 2008, Clinical pharmacology and therapeutics.

[93]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[94]  K. Maeda,et al.  INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS , 2006, Drug Metabolism and Disposition.

[95]  Y. Sugiyama,et al.  Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. , 1999, The Journal of pharmacology and experimental therapeutics.

[96]  D. Greenblatt,et al.  Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. , 2000, The Journal of pharmacology and experimental therapeutics.

[97]  J. Houston,et al.  Effect of Omeprazole on Diazepam Disposition in the Rat: in Vitro and in Vivo Studies , 1995, Pharmaceutical Research.

[98]  Y. Sugiyama,et al.  Uptake Is the Rate-limiting Step in the Overall Hepatic Elimination of Pravastatin at Steady-state in Rats , 1996, Pharmaceutical Research.

[99]  H. Yamazaki,et al.  Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[100]  Robert J Riley,et al.  EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.

[101]  C. Crespi Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research , 1995 .

[102]  N. Makita,et al.  Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access. , 2004, Molecular pharmacology.

[103]  Thierry Lavé,et al.  Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[104]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[105]  T. Baillie,et al.  Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.

[106]  R J Riley,et al.  The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. , 2006, Current drug metabolism.

[107]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[108]  M Baker,et al.  Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[109]  Diana Kazolias,et al.  Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport , 2006, Drug Metabolism and Disposition.

[110]  Kiyomi Ito,et al.  Comparison of the Use of Liver Models for Predicting Drug Clearance Using in Vitro Kinetic Data from Hepatic Microsomes and Isolated Hepatocytes , 2004, Pharmaceutical Research.

[111]  Y. Sugiyama,et al.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats , 1985, Journal of Pharmacokinetics and Biopharmaceutics.

[112]  T Iwatsubo,et al.  PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.

[113]  Hannah M Jones,et al.  SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.

[114]  D. Shen,et al.  First‐pass metabolism of midazolam by the human intestine , 1996, Clinical pharmacology and therapeutics.

[115]  Rui Gao,et al.  Pharmacogenetics of membrane transporters: a review of current approaches. , 2008, Methods in molecular biology.

[116]  D. Jaeck,et al.  Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[117]  Y. Sugiyama,et al.  Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. , 1997, The Journal of pharmacology and experimental therapeutics.

[118]  B. Burchell,et al.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. , 2002, The Journal of pharmacology and experimental therapeutics.

[119]  J S Harmatz,et al.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[120]  Y. Sugiyama,et al.  Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[121]  D. Keppler,et al.  Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1) , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[122]  K. Pang,et al.  Effect of diffusional barriers on drug and metabolite kinetics. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[123]  Albert P. Li Overview: hepatocytes and cryopreservation--a personal historical perspective. , 1999, Chemico-biological interactions.

[124]  T. Abe,et al.  Transcellular Transport of Organic Anions Across a Double-transfected Madin-Darby Canine Kidney II Cell Monolayer Expressing Both Human Organic Anion-transporting Polypeptide (OATP2/SLC21A6) and Multidrug Resistance-associated Protein 2 (MRP2/ABCC2)* , 2002, The Journal of Biological Chemistry.

[125]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[126]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[127]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[128]  T. Yamamoto,et al.  High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[129]  Peter J H Webborn,et al.  Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[130]  Y. Sugiyama,et al.  Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method , 1985, Journal of Pharmacokinetics and Biopharmaceutics.

[131]  R. Austin,et al.  A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES , 2005, Drug Metabolism and Disposition.

[132]  K. Pang,et al.  Theoretic aspects of pharmacokinetic drug interactions , 1977, Clinical pharmacology and therapeutics.

[133]  R J Riley,et al.  In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[134]  Y. Sugiyama,et al.  Function of uptake transporters for taurocholate and estradiol 17beta-D-glucuronide in cryopreserved human hepatocytes. , 2003, Drug metabolism and pharmacokinetics.

[135]  K. Maeda,et al.  Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[136]  Y. Sugiyama,et al.  Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[137]  M. Nakamura,et al.  Prediction of differences in in vivo oral clearance of N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers from in vitro metabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[138]  K. Nagata,et al.  Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. , 2006, Current drug metabolism.

[139]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[140]  Yuichi Sugiyama,et al.  Transporters as a determinant of drug clearance and tissue distribution. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[141]  P. Watkins Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation , 1995 .

[142]  J. Noordhoek,et al.  Influence of administration route and blood sampling site on the area under the curve. Assessment of gut wall, liver, and lung metabolism from a physiological model. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[143]  M. Kato,et al.  Intestinal first-pass metabolism of CYP3A4 substrates. , 2008, Drug metabolism and pharmacokinetics.

[144]  A. Barve,et al.  Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.

[145]  S. Wrighton,et al.  The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*† , 2001, Drug metabolism reviews.

[146]  I. Roots,et al.  Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations , 2008, European Journal of Clinical Pharmacology.